| Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas FC Geyer, A Li, AD Papanastasiou, A Smith, P Selenica, KA Burke, ... Nature communications 9 (1), 1816, 2018 | 132 | 2018 |
| HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway AE Smith, E Ferraro, A Safonov, CB Morales, EJA Lahuerta, Q Li, A Kulick, ... Nature Communications 12 (1), 6667, 2021 | 57 | 2021 |
| Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity AE Smith, S Chan, Z Wang, A McCloskey, Q Reilly, JZ Wang, HV Patel, ... Cancer research 83 (19), 3252-3263, 2023 | 11 | 2023 |
| Dressmaking: The Complete Step by Step Guide to Making Your Own Clothes A Smith Penguin, 2012 | 7 | 2012 |
| Antitumor activity of tipifarnib and PI3K pathway inhibitor in HRAS-associated HNSCC A Smith, S Chan, A McCloskey, H Vora, F Burrows, S Malik International Journal of Radiation Oncology, Biology, Physics 112 (5), e48, 2022 | 5 | 2022 |
| Manufacturing 2.0: Defining next-generation manufacturing C Mason, S Jacobson, A Smith AMR Research, 2007 | 5 | 2007 |
| Abstract PD4-13: Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic … FC Geyer, A Li, AD Papanastasiou, A Smith, P Selenica, KA Burke, ... Cancer Research 78 (4_Supplement), PD4-13-PD4-13, 2018 | 3 | 2018 |
| Dressmaking Step by Step: Classic Patterns and Essential Techniques for a Range of Beautiful Garments A Smith Penguin, 2015 | 2 | 2015 |
| Abstract B025: The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor … HV Patel, A Smith, S Chan, L Kessler, F Burrows, S Malik Molecular Cancer Therapeutics 22 (12_Supplement), B025-B025, 2023 | 1 | 2023 |
| Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance HV Patel, A Smith, S Chan, L Kessler, F Burrows, S Malik Cancer Research 83 (7_Supplement), 1079-1079, 2023 | 1 | 2023 |
| The effect of phosphorylation on transcription factor TaABF1’s ability to downregulate the Amy32b gene in cereal aleurone A Smith | 1 | 2014 |
| Abstract A012: Kmt2c/d loss primes urothelium for tumorigenesis and redistributes Menin to bivalent promoters N Wang, M Pachai, D Li, C Lee, S Warda, M Khudoynazarova, WH Cho, ... Clinical Cancer Research 30 (10_Supplement), A012-A012, 2024 | | 2024 |
| Methods of treating head and neck squamous cell carcinoma F Burrows, M Leoni, S Malik, VS Mishra, A Smith, H Soifer US Patent App. 18/355,850, 2024 | | 2024 |
| The next-generation farnesyltransferase inhibitor KO-2806 constrains compensatory signaling reactivation to deepen responses to KRASG12D inhibition A Smith, H Patel, S Chan, F Burrows, S Malik MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in … HV Patel, A Smith, S Chan, L Kessler, F Burrows, S Malik MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract B023: The next-generation farnesyltransferase inhibitor KO-2806 constrains compensatory signaling reactivation to deepen responses to KRASG12D inhibition A Smith, H Patel, S Chan, F Burrows, S Malik Molecular Cancer Therapeutics 22 (12_Supplement), B023-B023, 2023 | | 2023 |
| Tipifarnib potentiates the antitumor effects of PI3Kα inhibition inPIK3CA- andHRAS-dysregulated HNSCC via convergent inhibition of mTOR activity AE Smith, S Chan, Z Wang, A McCloskey, Q Reilly, JZ Wang, HV Patel, ... | | 2023 |
| Abstract B003: Inactivation mutations of Kmt2c/d license a molecular “field effect” and prime the urothelium for tumorigenesis N Wang, MR Pachai, D Li, C Lee, S Warda, G Xie, C Qian, WPE Wong, ... Cancer Research 82 (23_Supplement_2), B003-B003, 2022 | | 2022 |
| HNSCCs overexpressing wild-type HRAS are sensitive to combined tipifarnib and alpelisib treatment H Soifer, V Mishra, S Malik, A Smith, S Chan, L Kessler, F Burrows, ... European Journal of Cancer 174, S58, 2022 | | 2022 |
| Tipifarnib potentiates the antitumor effects of PI3Kα blockade in HNSCC via convergent inhibition of mTOR activity S Malik, A Smith, S Chan, A McCloskey, H Vora, Q Reilly, F Burrows | | 2022 |
